Hepatitis D and Compensated Cirrhosis: Starting Bulevirtide Without Knowing When to Stop
A single patient, chronic hepatitis D superinfecting his hepatitis B, with early cirrhosis on biopsy. The disagreement is whether starting a genuinely new drug now, likely for the rest of his life, is worth committing to before its own long-term relapse-after-stopping data have matured.
R.B., a 49-year-old immigration attorney, has known about his hepatitis B since a routine physical in his twenties, well-controlled for years on tenofovir with an undetectable HBV DNA. A persistently elevated ALT despite that viral suppression led his hepatologist to test for hepatitis D last year, which came back positive — a superinfection he'd likely carried, undetected, for longer than anyone can pin down. A liver biopsy done as part of that workup showed early, compensated cirrhosis: Child-Pugh A, no ascites, no encephalopathy, but real fibrotic architecture change that wasn't there on an ultrasound five years earlier. He still runs half-marathons on weekends and hasn't missed a day of work, but the biopsy result changed how urgently his own doctor wants to act.
Bulevirtide, an NTCP entry inhibitor that blocks the same bile-acid transporter hepatitis D uses to get into hepatocytes in the first place, is the first drug approved anywhere specifically for hepatitis D, and MYR301 is what earned it that approval: 48% of treated patients reached a combined virologic and biochemical response at week 48 against 2% of those whose treatment was delayed, with undetectable HDV RNA climbing from 20% at week 48 to half the cohort by week 144. It is an accelerated approval, granted on those surrogate markers, with clinical benefit still to be confirmed. The harder fact sits on the other side of the course. Stopping is not merely likely to fail — most patients who discontinue relapse virologically — it carries the label's boxed warning: severe acute exacerbation of both HDV and HBV after discontinuation, with cirrhotic patients specifically named as at risk of more severe flares and progression to hepatic decompensation. Child-Pugh A is still cirrhosis, which puts him inside that sentence rather than outside it. So the commitment being weighed today is not a bounded course and not simply an indefinite one; it is a course whose exit is itself a hazard requiring at least six months of monitoring if it is ever taken. His cirrhosis, once compensated becomes decompensated, is the argument for starting regardless; the fact that starting narrows his ability to safely stop is the argument for waiting. What makes his own case harder to sit with is the mismatch between how he looks and what his biopsy actually found — a man who still runs half-marathons most weekends, with no ascites, no encephalopathy, nothing on exam that would suggest cirrhosis to someone meeting him fresh, carrying fibrotic architecture change that simply wasn't there five years ago. His functional status is real and worth naming, but it isn't the same fact as his liver's actual structural trajectory, and the two are pulling the team's instincts in different directions.
Hepatology clinic, post-biopsy follow-up
I'd start bulevirtide today. His biopsy confirmed cirrhosis that wasn't there five years ago — his disease is actively progressing, not stable. MYR301's own efficacy data show meaningful HDV RNA suppression and biochemical response, and I don't think waiting for more mature durability data is free of cost when the thing we're waiting to avoid, decompensation, is exactly what's at stake if we wait too long.
The thing I keep coming back to is that the biopsy found something an ultrasound five years ago did not, and that we have no idea how much of that interval it took.
I'd hold off and monitor more closely instead. Starting bulevirtide isn't like starting a fixed-duration hepatitis C regimen — most patients who've tried stopping it have relapsed virologically, so we'd effectively be committing him to an indefinite therapy on a drug whose long-term safety picture is still maturing. He's compensated, functionally asymptomatic, and stable enough right now that I think we have real room to wait for more data.
I'm not disputing his biopsy shows real progression — I'm pointing out that "progression happened" and "progression is imminent enough to justify starting an effectively lifelong therapy today rather than in six months" aren't quite the same claim.
I'd lean toward starting, but I want to name what he's actually consenting to, because both of you have been calling it "indefinite therapy" and that undersells it. This drug carries a boxed warning for what happens when it stops: severe acute exacerbation of his hepatitis D and his hepatitis B, with cirrhosis named in the warning as the risk factor for a worse flare and for decompensation. He is Child-Pugh A, so he is in that sentence. Stopping is not a neutral return to baseline he can elect at any point — it is a separate clinical event needing at least six months of monitoring, and if he ever stops unilaterally because he feels well and injections are tiresome, that is the scenario the warning describes.
Framed that way the decision becomes his, with accurate expectations, rather than either of your positions being decided for him on the strength of how urgently his biopsy read. It doesn't settle whether to start today or in six months. It does change what consent has to cover, and it changes what we owe him if he ever wants to stop — which is a scheduled, monitored discontinuation, not a phone call.
Agreed: bulevirtide 8.5mg daily subcutaneously, started today, with tenofovir continued unchanged; an explicit informed-consent conversation covering both the likely-lifelong nature of the therapy and the boxed warning for severe acute HDV and HBV exacerbation on discontinuation, cirrhosis included as a stated risk factor; written instruction that he must not stop on his own, and that any planned discontinuation be accompanied by at least six months of hepatic monitoring; and bile acid levels followed given the drug's known asymptomatic elevation.
Not fully resolved: the infectious disease physician's underlying preference for waiting on a more mature evidence base remains a legitimate position the group didn't overturn, only outweighed by the hepatologist's read of his specific biopsy findings. The team agreed this urgency judgment would look different in a patient without confirmed new cirrhotic progression.